Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Sees Significant Growth in Short Interest

Tevogen Bio Holdings Inc. (NASDAQ:TVGN) saw a significant growth in short interest in the month of January. As of January 31st, there was short interest totalling 2,780,000 shares, a growth of 127.9% from the January 15th total of 1,220,000 shares. Approximately 11.2% of the shares of the stock are short sold. Based on an average daily trading volume, of 3,280,000 shares, the short-interest ratio is currently 0.8 days.

Tevogen Bio Price Performance

NASDAQ TVGN traded up $0.02 during trading on Friday, reaching $1.58. The company’s stock had a trading volume of 1,155,954 shares, compared to its average volume of 4,526,074. The firm has a fifty day moving average of $1.26 and a 200 day moving average of $1.08. Tevogen Bio has a one year low of $0.26 and a one year high of $21.09.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. HGC Investment Management Inc. purchased a new position in Tevogen Bio in the 3rd quarter worth approximately $82,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Tevogen Bio during the 4th quarter worth $38,000. JPMorgan Chase & Co. grew its position in Tevogen Bio by 74.2% in the fourth quarter. JPMorgan Chase & Co. now owns 39,207 shares of the company’s stock worth $40,000 after acquiring an additional 16,695 shares in the last quarter. Geode Capital Management LLC grew its position in Tevogen Bio by 31.2% in the fourth quarter. Geode Capital Management LLC now owns 451,851 shares of the company’s stock worth $465,000 after acquiring an additional 107,566 shares in the last quarter. Finally, Barclays PLC increased its stake in Tevogen Bio by 39.2% in the fourth quarter. Barclays PLC now owns 45,600 shares of the company’s stock valued at $48,000 after acquiring an additional 12,847 shares during the last quarter.

Tevogen Bio Company Profile

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.